AH23848, a thromboxane antagonist, suppresses ischaemia and reperfusion-induced arrhythmias in anaesthetized greyhounds

S. J. Coker, J. Parratt

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

1. The effects of the thromboxane antagonist AH23848 (1 mg kg-1 i.v.) were examined in anaesthetized greyhounds prepared for occlusion of the left anterior descending coronary artery with subsequent reperfusion after 40 min of myocardial ischaemia. 2. Pretreatment with AH23848 30 min before coronary artery occlusion reduced the number of ischaemia-induced extrasystoles to 339 ± 111 compared with 736 ± 153 in the control group. The incidence of ventricular fibrillation following reperfusion was also markedly reduced; 25% compared with 88% in the controls. 3. Late intervention with AH23848, 25 min after the onset of myocardial ischaemia did not significantly alter the incidence of reperfusion-induced ventricular fibrillation; 70% of the control group died and 60% of those that received AH23848. 4. The ischaemia-induced release of thromboxane A2 and prostacyclin was not altered by pretreatment with AH23848. 5. The results suggest that blockade of thromboxane receptors before myocardial ischaemia is an effective antiarrhythmic strategy in this model.

Original languageEnglish
Pages (from-to)259-264
Number of pages6
JournalBritish Journal of Pharmacology
Volume86
Issue number1
Publication statusPublished - 1985

Fingerprint

Thromboxanes
Reperfusion
Cardiac Arrhythmias
Ischemia
Myocardial Ischemia
Ventricular Fibrillation
Coronary Vessels
Thromboxane Receptors
Premature Cardiac Complexes
Control Groups
Thromboxane A2
Coronary Occlusion
Incidence
Epoprostenol
AH 23848

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{d181743126d943a49fd41c875bd01a4f,
title = "AH23848, a thromboxane antagonist, suppresses ischaemia and reperfusion-induced arrhythmias in anaesthetized greyhounds",
abstract = "1. The effects of the thromboxane antagonist AH23848 (1 mg kg-1 i.v.) were examined in anaesthetized greyhounds prepared for occlusion of the left anterior descending coronary artery with subsequent reperfusion after 40 min of myocardial ischaemia. 2. Pretreatment with AH23848 30 min before coronary artery occlusion reduced the number of ischaemia-induced extrasystoles to 339 ± 111 compared with 736 ± 153 in the control group. The incidence of ventricular fibrillation following reperfusion was also markedly reduced; 25{\%} compared with 88{\%} in the controls. 3. Late intervention with AH23848, 25 min after the onset of myocardial ischaemia did not significantly alter the incidence of reperfusion-induced ventricular fibrillation; 70{\%} of the control group died and 60{\%} of those that received AH23848. 4. The ischaemia-induced release of thromboxane A2 and prostacyclin was not altered by pretreatment with AH23848. 5. The results suggest that blockade of thromboxane receptors before myocardial ischaemia is an effective antiarrhythmic strategy in this model.",
author = "Coker, {S. J.} and J. Parratt",
year = "1985",
language = "English",
volume = "86",
pages = "259--264",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - AH23848, a thromboxane antagonist, suppresses ischaemia and reperfusion-induced arrhythmias in anaesthetized greyhounds

AU - Coker, S. J.

AU - Parratt, J.

PY - 1985

Y1 - 1985

N2 - 1. The effects of the thromboxane antagonist AH23848 (1 mg kg-1 i.v.) were examined in anaesthetized greyhounds prepared for occlusion of the left anterior descending coronary artery with subsequent reperfusion after 40 min of myocardial ischaemia. 2. Pretreatment with AH23848 30 min before coronary artery occlusion reduced the number of ischaemia-induced extrasystoles to 339 ± 111 compared with 736 ± 153 in the control group. The incidence of ventricular fibrillation following reperfusion was also markedly reduced; 25% compared with 88% in the controls. 3. Late intervention with AH23848, 25 min after the onset of myocardial ischaemia did not significantly alter the incidence of reperfusion-induced ventricular fibrillation; 70% of the control group died and 60% of those that received AH23848. 4. The ischaemia-induced release of thromboxane A2 and prostacyclin was not altered by pretreatment with AH23848. 5. The results suggest that blockade of thromboxane receptors before myocardial ischaemia is an effective antiarrhythmic strategy in this model.

AB - 1. The effects of the thromboxane antagonist AH23848 (1 mg kg-1 i.v.) were examined in anaesthetized greyhounds prepared for occlusion of the left anterior descending coronary artery with subsequent reperfusion after 40 min of myocardial ischaemia. 2. Pretreatment with AH23848 30 min before coronary artery occlusion reduced the number of ischaemia-induced extrasystoles to 339 ± 111 compared with 736 ± 153 in the control group. The incidence of ventricular fibrillation following reperfusion was also markedly reduced; 25% compared with 88% in the controls. 3. Late intervention with AH23848, 25 min after the onset of myocardial ischaemia did not significantly alter the incidence of reperfusion-induced ventricular fibrillation; 70% of the control group died and 60% of those that received AH23848. 4. The ischaemia-induced release of thromboxane A2 and prostacyclin was not altered by pretreatment with AH23848. 5. The results suggest that blockade of thromboxane receptors before myocardial ischaemia is an effective antiarrhythmic strategy in this model.

UR - http://www.scopus.com/inward/record.url?scp=0022389149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022389149&partnerID=8YFLogxK

M3 - Article

C2 - 3840397

AN - SCOPUS:0022389149

VL - 86

SP - 259

EP - 264

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 1

ER -